voda schreef op 10 september 2023 09:29:
Pharming Group: Pipeline Progresses With APDS Phase 3 Initiation
Sep. 09, 2023 12:30 PM ET Pharming Group N.V. (PHAR)
Summary
- Pharming Group NV is a biotechnology firm known for its unique approach to addressing rare and genetic diseases.
- The company's financials show growth in revenue, primarily driven by strong sales of their leading therapy, Ruconest.
- Pharming's expansion into organ transplantation fields adds a new dimension to their growth prospects, but challenges remain in gaining acceptance and assessing the impact on their income.
Voor veel meer, zie de link:
seekingalpha.com/article/4634103-phar...